| Record Information |
| Version |
3.5 |
| Creation Date |
2005-11-16 08:48:42 -0700 |
| Update Date |
2013-02-08 17:08:10 -0700 |
| HMDB ID |
HMDB00248 |
| Secondary Accession Numbers |
|
| Metabolite Identification |
| Common Name |
Thyroxine |
| Description |
The thyronamines function via some unknown mechanism to inhibit neuronal activity; this plays an important role in the hibernation cycles of mammals. One effect of administering the thyronamines is a severe drop in body temperature. Iodide is actively absorbed from the bloodstream and concentrated in the thyroid follicles. (If there is a deficiency of dietary iodine, the thyroid enlarges in an attempt to trap more iodine, resulting in goitre.) Via a reaction with the enzyme thyroperoxidase, iodine is covalently bound to tyrosine residues in the thyroglobulin molecules, forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). Linking two moieties of DIT produces thyroxine. Combining one particle of MIT and one particle of DIT produces triiodothyronine. Both T3 and T4 are used to treat thyroid hormone deficiency (hypothyroidism). They are both absorbed well by the gut, so can be given orally. Levothyroxine, the most commonly used synthetic thyroxine form, is a stereoisomer of physiological thyroxine, which is metabolized more slowly and hence usually only needs once-daily administration. Natural desiccated thyroid hormones, which are derived from pig thyroid glands, are a "natural" hypothyroid treatment containing 20% T3 and traces of T2, T1 and calcitonin. this plays an important role in the hibernation cycles of mammals. One effect of administering the thyronamines is a severe drop in body temperature. The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. The thyronamines function via some unknown mechanism to inhibit neuronal activity. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (-)-Thyroxine
- 3,3',5,5''-Tetraiodo-L-thyronine
- 3,3',5,5'-Tetraiodo-L-thyronine
- 3,5,3',5'-Tetraiodo-L-Thyronine
- 3,5,3',5'-Tetraiodothyronine
- 3,5,3'5'-Tetraiodo-L-thyronine
- D-Thyroxine
- DL-Thyroxin
- Henning
- L-3,5,3',5'-Tetraiodothyronine
- L-Thyroxin
- L-Thyroxine
- Laevothyroxinum
- Levothroid
- Levothyroxin
- Levothyroxine
- Levothyroxine sodium
- Levothyroxinum
- Levoxyl
- Prestwick_548
- Synthroid
- T4
- Tetraiodothyronine
- Tetramet
- THX
- Thyratabs
- Thyrax
- Thyreoideum
- Thyroxin
- Thyroxinal
- Thyroxine
- Thyroxine I 125
- Thyroxine iodine
|
| Chemical Formula |
C15H11I4NO4 |
| Average Molecular Weight |
776.87 |
| Monoisotopic Molecular Weight |
776.686681525 |
| IUPAC Name |
(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid |
| Traditional IUPAC Name |
levothyroxine |
| CAS Registry Number |
51-48-9 |
| SMILES |
N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O |
| InChI Identifier |
InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1 |
| InChI Key |
XUIIKFGFIJCVMT-LBPRGKRZSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Amino Acids, Peptides, and Analogues |
| Class |
Amino Acids and Derivatives |
| Sub Class |
Alpha Amino Acids and Derivatives |
| Other Descriptors |
- Aromatic Homomonocyclic Compounds
- Aromatic Homopolycyclic Compounds
- a hormone(Cyc)
- amino acid zwitterion(ChEBI)
- an iodoaromatic compound(Cyc)
|
| Substituents |
- Amphetamine Or Derivative
- Aryl Iodide
- Carboxylic Acid
- Iodobenzene
- Methoxyphenol
- Organoiodide
- Phenethylamine
- Phenol
- Phenol Derivative
- Primary Aliphatic Amine (Alkylamine)
|
| Direct Parent |
Alpha Amino Acids and Derivatives |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Protein synthesis, amino acid biosynthesis
|
| Application |
Not Available
|
| Cellular locations |
- Cytoplasm
- Extracellular
- Membrane (predicted from logP)
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
235.5 °C |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
Not Available |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|
|
| Biological Properties |
| Cellular Locations |
- Cytoplasm
- Extracellular
- Membrane (predicted from logP)
|
| Biofluid Locations |
|
| Tissue Location |
- Muscle
- Skeletal Muscle
- Fibroblasts
- Intestine
- Neuron
- Placenta
- Testes
- Thyroid Gland
- Myelin
- Prostate
- Adipose Tissue
- Nerve Cells
- Platelet
- Gonads
- Spleen
|
| Pathways |
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.000009 - 0.000023 uM |
Not Available |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
0.12 +/- 0.0061 uM |
Children (1-13 year old) |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
0.000016 (0.0000064-0.000064) uM |
Adult (>18 years old) |
Both |
Normal
|
|
| Blood |
Detected and Quantified |
|
0.0000144 +/- 0.0000036 uM |
Adolescent (13-18 years old) |
Female |
Normal
|
|
| Blood |
Detected and Quantified |
|
0.00002 (0.00001-0.00003) uM |
Adult (>18 years old) |
Both |
Normal
|
|
| Saliva |
Detected and Quantified |
|
0.0 - 1.0 uM |
Adult (>18 years old) |
Both |
Normal
|
|
| Urine |
Detected and Quantified |
|
0.00032 +/- 0.00015 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal
|
|
|
| Abnormal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.0000185 +/- 0.0000052 uM |
Adult (>18 years old) |
Both |
Hypothyroidism
|
|
| Blood |
Detected and Quantified |
|
0.057 +/- 0.0058 uM |
Children (1-13 year old) |
Both |
Severely malnourished children
|
|
| Blood |
Detected and Quantified |
|
0.000011 +/- 0.0000016 uM |
Adolescent (13-18 years old) |
Female |
Anorexia nervosa
|
|
| Urine |
Detected and Quantified |
|
0.0015 +/- 0.00154 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Proteinuria
|
|
|
| Associated Disorders and Diseases |
| Disease References |
| Anorexia nervosa |
- Capo-chichi CD, Gueant JL, Lefebvre E, Bennani N, Lorentz E, Vidailhet C, Vidailhet M: Riboflavin and riboflavin-derived cofactors in adolescent girls with anorexia nervosa. Am J Clin Nutr. 1999 Apr;69(4):672-8.
Pubmed: 10197568
|
| Hypothyroidism |
- Sjoberg S, Eriksson M, Nordin C: L-thyroxine treatment and neurotransmitter levels in the cerebrospinal fluid of hypothyroid patients: a pilot study. Eur J Endocrinol. 1998 Nov;139(5):493-7.
Pubmed: 9849813
|
| Proteinuria |
- Chandurkar V, Shik J, Randell E: Exacerbation of underlying hypothyroidism caused by proteinuria and induction of urinary thyroxine loss: case report and subsequent investigation. Endocr Pract. 2008 Jan-Feb;14(1):97-103.
Pubmed: 18238748
|
|
| Associated OMIM IDs |
|
| External Links |
| DrugBank ID |
Not Available |
| DrugBank Metabolite ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB021829 |
| KNApSAcK ID |
Not Available |
| Chemspider ID |
5614  |
| KEGG Compound ID |
C01829  |
| BioCyc ID |
L-THYROXINE  |
| BiGG ID |
38499  |
| Wikipedia Link |
Thyroxine  |
| NuGOwiki Link |
HMDB00248  |
| Metagene Link |
HMDB00248  |
| METLIN ID |
439  |
| PubChem Compound |
5819  |
| PDB ID |
T44  |
| ChEBI ID |
18332  |
| References |
| Synthesis Reference |
Martinovich, V. P.; Katok, Ya. M.; Fil'chenkov, N. A.; Sviridov, O. V. Conjugated synthesis of L-thyroxine and L-triiodothyronine. Vestsi Natsyyanal'nai Akademii Navuk Belarusi, Seryya Khimichnykh Navuk (2004), (1), 85-92. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Kahan IL, Varsanyi-Nagy M, Toth M, Nadrai A: The possible role of tear fluid thyroxine in keratoconus development. Exp Eye Res. 1990 Apr;50(4):339-43.
Pubmed: 2338121
- Jagannathan NR, Tandon N, Raghunathan P, Kochupillai N: Reversal of abnormalities of myelination by thyroxine therapy in congenital hypothyroidism: localized in vivo proton magnetic resonance spectroscopy (MRS) study. Brain Res Dev Brain Res. 1998 Aug 8;109(2):179-86.
Pubmed: 9729372
- Kurz W, Wittlinger G, Litmanovitch YI, Romanoff H, Pfeifer Y, Tal E, Sulman FG: Effect of manual lymph drainage massage on urinary excretion of neurohormones and minerals in chronic lymphedema. Angiology. 1978 Oct;29(10):764-72.
Pubmed: 717839
- Randolph VS: Four clinical chemistry analyses for pediatric patients: glycosylated hemoglobin, free bilirubin, sweat electrolytes, neonatal thyroxine. Am J Med Technol. 1982 Jan;48(1):15-22.
Pubmed: 7041647
- van Wassenaer AG, Stulp MR, Valianpour F, Tamminga P, Ris Stalpers C, de Randamie JS, van Beusekom C, de Vijlder JJ: The quantity of thyroid hormone in human milk is too low to influence plasma thyroid hormone levels in the very preterm infant. Clin Endocrinol (Oxf). 2002 May;56(5):621-7.
Pubmed: 12030913
- Etling N, Gehin-Fouque F, Vielh JP, Gautray JP: The iodine content of amniotic fluid and placental transfer of iodinated drugs. Obstet Gynecol. 1979 Mar;53(3):376-80.
Pubmed: 424113
- Zenovko EI, Pavlov BA, Koreshkov GG, Gudukina GN, Sonkina EG: [Hypothalamo-pituitary-thyroid system in patients with rheumatoid arthritis] Ter Arkh. 1998;70(1):49-52.
Pubmed: 9532653
- Hays MT, McGuire RA, Hoogeveen JT, Diezeraad KN: Measurement method for radioactive thyroxine, triiodothyronine, iodide, and iodoprotein in samples with low activity. J Nucl Med. 1980 Mar;21(3):225-32.
Pubmed: 7365515
- Benvenga S, Alesci S, Trimarchi F: High-density lipoprotein-facilitated entry of thyroid hormones into cells: a mechanism different from the low-density lipoprotein-facilitated entry. Thyroid. 2002 Jul;12(7):547-56.
Pubmed: 12193297
- Gil'miiarova FN, Pervova IuV, Radomskaia VM, Gergel' NI, Tarasova SV: [Levels of unified metabolites and thyroid hormones in blood and oral fluid of children with minimal brain dysfunction] Biomed Khim. 2004 Mar-Apr;50(2):204-10.
Pubmed: 15179829
- Hausman GJ, Wright JT, Latimer A, Watson R, Martin RJ: The influence of human growth hormone (GH) and thyroxine (T4) on the differentiation of adipose tissue in the fetus. Obes Res. 1993 Sep;1(5):345-56.
Pubmed: 16350585
- Gil-Loyzaga P, Remezal M, Mollicone R, Ibanez A, Oriol R: H and B human blood-group antigen expression in cochlear hair cells is modulated by thyroxine. Cell Tissue Res. 1994 May;276(2):239-43.
Pubmed: 8020061
- Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J: Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005 Mar 15;142(6):412-24.
Pubmed: 15767619
- Bode HH, Vanjonack WJ, Crawford JD: Mitigation of cretinism by breast-feeding. Pediatrics. 1978 Jul;62(1):13-6.
Pubmed: 683777
- Marks P, Anderson J, Vincent R: Aldosterone in myxoedema. Lancet. 1978 Dec 16;2(8103):1277-8.
Pubmed: 82781
- Sutherland RL, Simpson-Morgan MW: The thyroxine-binding properties of serum proteins. A competitive binding technique employing sephadex G-25. J Endocrinol. 1975 Jun;65(3):319-32.
Pubmed: 807668
- Braley-Mullen H, Sharp GC: A thyroxine-containing thyroglobulin peptide induces both lymphocytic and granulomatous forms of experimental autoimmune thyroiditis. J Autoimmun. 1997 Dec;10(6):531-40.
Pubmed: 9451592
- Raghu P, Reddy GB, Sivakumar B: Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization. Arch Biochem Biophys. 2002 Apr 1;400(1):43-7.
Pubmed: 11913969
- Hekimsoy Z, Oktem IK: Serum creatine kinase levels in overt and subclinical hypothyroidism. Endocr Res. 2005;31(3):171-5.
Pubmed: 16392619
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4.
Pubmed: 19212411
|